SAN DIEGO, RESEARCH TRIANGLE PARK, NC – May 17, 2022 — Creyon Bio, Inc. (“Creyon Bio”), a drug development company engineering RNA-based medicines and their components (oligonucleotide-based medicines or OBMs) with predictable safety and efficacy profiles, today announced that David Fajgenbaum, MD, MBA, MSc, will serve as a Company Advisor and Board Observer. Dr. Fajgenbaum is a recognized thought leader in innovative biomedical research and drug development, particularly for rare disease, and will help Creyon Bio’s work to align and connect with regulatory, patient, and clinical communities.

“There are so many diseases and patients that do not have any effective treatment options even though medical technologies and tools exist that could help them. Creyon is helping to advance those technologies to help patients as quickly as possible,” said Dr. Fajgenbaum. “I am thrilled to support the Creyon team and excited by the platform they are building and their commitment to improving outcomes for patients.”

Dr. Fajgenbaum is an Assistant Professor of Translational Medicine and Human Genetics at the Perelman School of Medicine at the University of Pennsylvania and Associate Director of Patient Impact at the Penn Orphan Disease Center. An NIH-funded physician-scientist, he has dedicated his life to discovering new treatments and cures for deadly disorders including idiopathic multicentric Castleman disease (iMCD), which he was diagnosed with during medical school. He is currently in remission because of a precision treatment that he identified and that has been repurposed for iMCD. He described his journey to a precision treatment for his disease in his 2019 national bestselling memoir Chasing My Cure: A Doctor’s Race to Turn Hope Into Action. As the Co-Founder and President of the Castleman Disease Collaborative Network (CDCN), Dr. Fajgenbaum is a champion for the application of business-inspired solutions to advance iMCD research and works to apply this innovative model for accelerating rare disease research and drug repurposing. Dr. Fajenbaum is also Co-director of the advisory committee for the CURE Drug Repurposing Collaboratory, which is a FDA/NIH/C-Path public-private partnership, and a Board Member of the Reagan-Udall Foundation for the FDA.

“David’s focus on patients and their needs is unwavering, and his passion for creating a better world is compelling. We are excited to have David join our team as a company advisor and official board observer,” said Christopher Hart, Ph.D., Co-Founder, Chief Executive Officer, and President of Creyon Bio. “As we advance the Creyon Platform, David’s deep understanding of the rare community at a personal, medical, scientific and regulatory level will help shape our efforts and strategies.”

About Creyon Bio, Inc.

Creyon Bio is a pre-clinical stage company reimagining drug development as it should be, using a data-first approach for generating uniquely powerful datasets and developing machine learning models to uncover the engineering principles that make precision oligonucleotide-based medicines possible for patient populations of all sizes. To learn more, visit


Media Contact:

Lissette Steele
Verge Scientific Communications